EU opens a formal investigation into Sanofi (SAN FP) over the promotion of flu vaccine for vulnerable patients

The European Commission has opened a formal antitrust investigation to assess whether Sanofi has breached EU competition rules by carrying out a communication campaign that disparages the only rival flu vaccine recommended for vulnerable patients with risk factors. The Commission is concerned that Sanofi pursued a misleading communication campaign to disparage Fluad by portraying it as inferior to Efluelda, going against national vaccination recommendations in several Member States. The campaign primarily targeted healthcare professionals in Germany and France.